AKT1 and neoplasm: Among the studies included in the aforementioned metanalysis, a noteworthy observation was derived from the targeted next-generation sequencing (tNGS) performed on 185 tumor samples obtained almost entirely from de novo mHSPC patients enrolled in the STAMPEDE trial: PI3K pathway aberrations were observed in 43% of the cases, which were due to PTEN copy-number loss (34%) and/or inactivating mutations in PIK3 or AKT (18%) [64].